Literature DB >> 20847032

Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer.

A A Martoni1, F Di Fabio2, C Pinto2, P Castellucci3, S Pini2, C Ceccarelli4, D Cuicchi5, B Iacopino6, P Di Tullio2, S Giaquinta2, L Tardio4, R Lombardi5, S Fanti3, B Cola5.   

Abstract

BACKGROUND: 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) was carried out before and after neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery for locally advanced rectal cancer (LARC). The aim of this study was to define its predictive and prognostic values. PATIENTS AND METHODS: Patients with cT3-T4 N-/+ carcinoma of medium/low rectum received daily 5-fluorouracil-based chemotherapy infusion and radiation therapy on 6-week period followed by surgery 7-8 weeks later. Tumour metabolic activity, expressed as maximum standardised uptake value (SUV-1 = at baseline and SUV-2 = pre-surgery), was calculated in the most active tumour site. Predictive and prognostic values of SUV-1, SUV-2 and Δ-SUV (percentage change of SUV-1 - SUV-2) were analysed towards pathological response (pR) in the surgical specimen and disease recurrence, respectively.
RESULTS: Eighty consecutive patients entered the study. SUV-1, SUV-2 and Δ-SUV appeared singly correlated with pR, but not one of them resulted an independent predictive factor at multivariate analysis. After a median follow-up of 44 months, 13 patients (16.2%) presented local and/or distant recurrence. SUV-2 ≤5 was associated with lower incidence of disease recurrence and resulted prognostic factor at multivariate analysis.
CONCLUSIONS: Dual-time FDG-PET/CT in patients with LARC treated with NCRT and radical surgery supplies limited predictive information. However, an optimal metabolic response appears associated with a favourable patient outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847032     DOI: 10.1093/annonc/mdq433

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  25 in total

1.  Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study.

Authors:  Farrokh Dehdashti; Perry W Grigsby; Robert J Myerson; Ilke Nalbantoglu; Changqing Ma; Barry A Siegel
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

2.  Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.

Authors:  Michael A Fischer; Bart Vrugt; Hatem Alkadhi; Dieter Hahnloser; Thomas F Hany; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-24       Impact factor: 9.236

3.  Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.

Authors:  Antonio Avallone; Luigi Aloj; Corradina Caracò; Paolo Delrio; Biagio Pecori; Fabiana Tatangelo; Nigel Scott; Rossana Casaretti; Francesca Di Gennaro; Massimo Montano; Lucrezia Silvestro; Alfredo Budillon; Secondo Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

4.  Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy.

Authors:  Anna Margherita Maffione; Alice Ferretti; Gaia Grassetto; Elena Bellan; Carlo Capirci; Sotirios Chondrogiannis; Marcello Gava; Maria Cristina Marzola; Lucia Rampin; Claudia Bondesan; Patrick M Colletti; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

5.  Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging.

Authors:  R O Perez; A Habr-Gama; G P São Julião; P B Lynn; C Sabbagh; I Proscurshim; F G Campos; J Gama-Rodrigues; S C Nahas; C A Buchpiguel
Journal:  Tech Coloproctol       Date:  2014-02-08       Impact factor: 3.781

6.  Prognostic value of 18F-FDG uptake by regional lymph nodes on pretreatment PET/CT in patients with resectable colorectal cancer.

Authors:  Byung Hyun Byun; Sun Mi Moon; Ui Sup Shin; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

7.  The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.

Authors:  Lucia Leccisotti; Maria Antonietta Gambacorta; Chiara de Waure; Antonella Stefanelli; Brunella Barbaro; Fabio Maria Vecchio; Claudio Coco; Roberto Persiani; Antonio Crucitti; Antonino Pio Tortorelli; Alessandro Giordano; Vincenzo Valentini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-17       Impact factor: 9.236

Review 8.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

9.  Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer.

Authors:  Byoung Yong Shim; Ji-Han Jung; Kang-Moon Lee; Hyung-Jin Kim; Sook Hee Hong; Sung Hwan Kim; Der Sheng Sun; Hyeon-Min Cho
Journal:  Int J Colorectal Dis       Date:  2012-07-31       Impact factor: 2.571

10.  (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Selin Carkaci; Christopher T Sherman; Efe Ozkan; Beatriz E Adrada; Wei Wei; Eric M Rohren; Osama R Mawlawi; Naoto T Ueno; Thomas A Buchholz; Wei T Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.